Heather Johnson

Intravitreal anti-vascular endothelial growth factor (VEGF) therapy slows or stops damage that occurs in wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other retinal ...

Gemini Therapeutics, a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market ...

What a difference a few months makes. Outlook Therapeutics’ stock price plunged last August on the heels of top-line results from the NORSE 1 clinical ...

With the acquisition of Vienna-based biotech Panoptes Pharma, Eye Gate Pharmaceuticals has expanded its pipeline of nonsteroidal products targeting ocular inflammation by adding Panoptes’ PP-001, ...

Novartis is doubling down on its mission to end preventable blindness, which has translated into a host of moves to strengthen its commitment to age-related ...

While scuba diving in the Caribbean, John Berdahl, MD, came up with the idea that led him to found Equinox. Five years later, that company ...

Opthea, the Australia-based biopharma developing a novel therapy to treat exudative retinal diseases, closed out a busy summer with a US Securities and Exchange Commission ...

They won’t help you search the Internet, but Kubota Vision’s glasses may help slow the progression of myopia, and possibly even prevent the condition when ...

Ophthalmology drugs, particularly drugs associated with surgeries and retinal disease, took a beating in Q2 because of COVID-19 disruptions. Things may be looking up for ...

The glaucoma space has been dominated by a host of products designed to lower intraocular pressure (IOP) – minimally invasive glaucoma surgery (MIGS) devices and ...

Editor's Note: The FDA just approved Allergan's Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on ...

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...